Guest Post by Steve Kirsch

The drug works great. But the FDA doesn’t want anyone to know that. Why? Because they are corrupt.

Summary

Fluvoxamine has a systematic review and meta-analysis published in a top medical journal. You cannot get any better than that. It’s the “gold standard” of medical evidence.

So when a group of scientists applied for an EUA for fluvoxamine, what did the FDA do? They rejected the drug for “insufficient evidence” just like they always do for ivermectin.

Everyone is stunned, but nobody is surprised. How can the FDA say a drug which meets the “gold standard” of evidence has “insufficient evidence”?

The FDA approved Molnupiravir which was less effective. Why not fluvoxamine?

ICER, a non-profit known as the nation’s drug pricing watchdog, did a review of the evidence and determined that fluvoxamine evidence is superior to Molnupiravir.

It can’t be more clear than this. The reason is pure corruption.

Continue reading “How the FDA justified rejecting an EUA for fluvoxamine”

Guest Post by Pierre Kory

The Alphabet Health Agencies Ignoring of the Repurposed Drug Fluvoxamine

**Authors note: Big thanks to Steve Kirsch and his Covid Early Treatment Foundation’s efforts to support research into and knowledge of the highly effective COVID-19 medicine fluvoxamine. The FLCCC added the medicine 8 months ago. The agencies and societies contnue to ignore the now massive evidence base behind it.

My Op-Ed written at the beginning of the Omicron wave:

Omicron emerging in the United States and news of the first reported death in the United Kingdom remind us how little we understand the novel coronavirus, and with vaccines less effective against the new variant, how much we are in need of additional ways to fight it. To broaden our knowledge of COVID-19 and identify the best ways to treat and prevent it, doctors should be able to use every possible safe means at their disposal to help patients. Unfortunately, that is impossible in our current political climate.

Continue reading “The Alphabet Health Agencies Ignoring of the Repurposed Drug Fluvoxamine”